December 12, 2014 – RNA Viruses: Biology and Countermeasures

FujiFilm and MediVector, together with Cell Host & Microbe are sponsoring a scientific Symposium on Influenza on December 12 at the American Academy of Arts & Sciences. Speakers: Ian Wilson, The Scripps Institute Broad Neutralization of Influenza Virus and Implications for Vaccine Design Sean Whelan, Harvard Medical School RNA synthesis machines of negative-strand viruses Stephen […]

First Patient Enrolled in Northern Hemisphere for Phase 3 Study of Favipiravir for Influenza

BOSTON, Jan. 16, 2014 — MediVector, Inc. today announced the enrollment of its first patient in the United States in one of two FAVOR favipiravir Phase 3 studies in adults with uncomplicated influenza.  This multi-center, double-blind, placebo-controlled study is expected to enroll over 1,000 patients in participating clinics and practices in North, Central, and South America. “The […]

DoD’s BioDefense Therapeutics Announces First Patient Enrolled in Phase 3 Clinical Trials for Favipiravir

BioDefense Therapeutics (BD Tx)—a Joint Product Management office within the U.S. Department of Defense (DoD)—announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir (T-705a). The drug is an investigational flu treatment candidate with broad-spectrum potential being developed by BD Tx through a contract with Boston-based MediVector, Inc. Read more.